Luca Issi
Stock Analyst at RBC Capital
(0.80)
# 2,837
Out of 4,412 analysts
106
Total ratings
20.59%
Success rate
-19.1%
Average return
Main Sectors:
Top Industries:
23 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Initiates: Outperform | $77 | $44.24 | +74.05% | 1 | Apr 22, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $35 → $40 | $23.25 | +72.04% | 3 | Apr 15, 2024 | |
| MRNA Moderna | Reiterates: Outperform | $125 | $107.97 | +15.77% | 6 | Mar 28, 2024 | |
| BLUE bluebird bio | Reiterates: Sector Perform | $8 | $0.92 | +766.93% | 3 | Mar 27, 2024 | |
| KRRO Korro Bio | Maintains: Outperform | $70 → $90 | $62.93 | +43.02% | 3 | Mar 27, 2024 | |
| ADVM Adverum Biotechnologies | Maintains: Sector Perform | $30 → $20 | $9.19 | +117.63% | 4 | Mar 19, 2024 | |
| MGTX MeiraGTx Holdings | Reiterates: Outperform | $11 | $4.80 | +129.17% | 3 | Mar 15, 2024 | |
| ALLO Allogene Therapeutics | Reiterates: Outperform | $10 | $2.89 | +246.02% | 6 | Mar 15, 2024 | |
| SGMO Sangamo Therapeutics | Reiterates: Sector Perform | $2 | $0.52 | +286.25% | 5 | Mar 14, 2024 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $22 → $24 | $12.50 | +92.00% | 2 | Mar 12, 2024 | |
| CRBU Caribou Biosciences | Reiterates: Outperform | $19 | $3.71 | +412.13% | 4 | Mar 12, 2024 | |
| RGNX REGENXBIO | Upgrades: Outperform | $20 → $35 | $16.19 | +116.18% | 6 | Mar 8, 2024 | |
| WVE Wave Life Sciences | Reiterates: Sector Perform | $5 | $4.66 | +7.30% | 3 | Mar 7, 2024 | |
| VERV Verve Therapeutics | Reiterates: Outperform | $35 | $6.16 | +468.18% | 4 | Feb 28, 2024 | |
| BEAM Beam Therapeutics | Maintains: Sector Perform | $27 → $35 | $21.38 | +63.70% | 3 | Feb 28, 2024 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Sector Perform | $100 | $80.91 | +23.59% | 6 | Feb 23, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Sector Perform | $57 → $66 | $53.91 | +22.43% | 8 | Feb 22, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $235 | $143.31 | +63.98% | 15 | Feb 21, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Outperform | $50 | $22.12 | +126.04% | 6 | Feb 7, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $65 → $70 | $41.59 | +68.31% | 5 | Jan 26, 2024 | |
| QURE uniQure | Reiterates: Outperform | $28 | $4.53 | +518.10% | 3 | Jan 16, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $80 → $70 | $20.76 | +237.19% | 2 | Nov 10, 2023 | |
| EDIT Editas Medicine | Maintains: Sector Perform | $7 → $8 | $5.32 | +50.38% | 5 | May 8, 2023 |
Ultragenyx Pharmaceutical
Apr 22, 2024
Initiates: Outperform
Price Target: $77
Current: $44.24
Upside: +74.05%
4D Molecular Therapeutics
Apr 15, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $23.25
Upside: +72.04%
Moderna
Mar 28, 2024
Reiterates: Outperform
Price Target: $125
Current: $107.97
Upside: +15.77%
bluebird bio
Mar 27, 2024
Reiterates: Sector Perform
Price Target: $8
Current: $0.92
Upside: +766.93%
Korro Bio
Mar 27, 2024
Maintains: Outperform
Price Target: $70 → $90
Current: $62.93
Upside: +43.02%
Adverum Biotechnologies
Mar 19, 2024
Maintains: Sector Perform
Price Target: $30 → $20
Current: $9.19
Upside: +117.63%
MeiraGTx Holdings
Mar 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.80
Upside: +129.17%
Allogene Therapeutics
Mar 15, 2024
Reiterates: Outperform
Price Target: $10
Current: $2.89
Upside: +246.02%
Sangamo Therapeutics
Mar 14, 2024
Reiterates: Sector Perform
Price Target: $2
Current: $0.52
Upside: +286.25%
Lexeo Therapeutics
Mar 12, 2024
Maintains: Outperform
Price Target: $22 → $24
Current: $12.50
Upside: +92.00%
Caribou Biosciences
Mar 12, 2024
Reiterates: Outperform
Price Target: $19
Current: $3.71
Upside: +412.13%
REGENXBIO
Mar 8, 2024
Upgrades: Outperform
Price Target: $20 → $35
Current: $16.19
Upside: +116.18%
Wave Life Sciences
Mar 7, 2024
Reiterates: Sector Perform
Price Target: $5
Current: $4.66
Upside: +7.30%
Verve Therapeutics
Feb 28, 2024
Reiterates: Outperform
Price Target: $35
Current: $6.16
Upside: +468.18%
Beam Therapeutics
Feb 28, 2024
Maintains: Sector Perform
Price Target: $27 → $35
Current: $21.38
Upside: +63.70%
BioMarin Pharmaceutical
Feb 23, 2024
Reiterates: Sector Perform
Price Target: $100
Current: $80.91
Upside: +23.59%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Sector Perform
Price Target: $57 → $66
Current: $53.91
Upside: +22.43%
Alnylam Pharmaceuticals
Feb 21, 2024
Reiterates: Outperform
Price Target: $235
Current: $143.31
Upside: +63.98%
Arrowhead Pharmaceuticals
Feb 7, 2024
Reiterates: Outperform
Price Target: $50
Current: $22.12
Upside: +126.04%
Ionis Pharmaceuticals
Jan 26, 2024
Maintains: Outperform
Price Target: $65 → $70
Current: $41.59
Upside: +68.31%
uniQure
Jan 16, 2024
Reiterates: Outperform
Price Target: $28
Current: $4.53
Upside: +518.10%
Intellia Therapeutics
Nov 10, 2023
Maintains: Outperform
Price Target: $80 → $70
Current: $20.76
Upside: +237.19%
Editas Medicine
May 8, 2023
Maintains: Sector Perform
Price Target: $7 → $8
Current: $5.32
Upside: +50.38%